Sanofi/AstraZeneca’s Nirsevimab Is Set To Transform RSV Treatment In Infants

 
• By Brenda Sandburg
  
RSV infants
The biologics license application for the first RSV prophylaxis for all infants is under FDA review. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Interviews

More from Pink Sheet